XML 30 R12.htm IDEA: XBRL DOCUMENT

Note 5 - Warrants

12 Months Ended

Dec. 31, 2021

5. Warrants

Upon its issuance of warrants to purchase shares of common stock, the Company evaluates the terms of the warrant issue to determine the appropriate accounting and classification of the warrant issue pursuant to FASB ASC Topic 480, Distinguishing Liabilities from Equity, FASB ASC Topic 505, Equity, FASB ASC 815, Derivatives and Hedging, and ASC 718, Compensation - Stock Compensation. Warrants are classified as liabilities when the Company may be required to settle a warrant exercise in cash and classified as equity when the Company settles a warrant exercise in shares of its common stock.

Liability classified warrants are valued at fair value at the date of issue and at each reporting date pursuant to FASB ASC 820, Fair Value Measurement, (ASC 820) and is reflected as a warrant liability on our consolidated balance sheet with the change in the warrant liability during each reporting period is reflected as a gain (loss) from change in fair value of warrant liability in our consolidated statement of operations.

Equity classified warrants issued to non-employees in exchange for services are accounted for in accordance with ASC 718 which requires all stock-based payments be recognized in the consolidated statements of operations based on their fair value. For further information, see Note 2. Basis of presentation, principles of consolidation and significant accounting policies – Stock-based Compensation.

At December 31, 2021 and 2020, the Company has the following warrants outstanding:

	*Number of Shares Under Outstanding Warrants at December 31, 2021*		*Number of Shares Under Outstanding Warrants at December 31, 2020*		*Weighted Average Exercise Price at December 31, 2021*		*Remaining Contractual Life at December 31, 2021 (Years)*
Liability Classified Warrants ⁽¹⁾
Issued February 2017		67,349		67,349	$	8.42		0.1
Issued February 2018		378,951		378,951		16.80		1.6
Issued June 2018 ⁽²⁾		123,836		123,836		12.20		1.9
Issued March 2019		263,507		263,507		6.60		2.2
Issued April 2019		875,001		875,001		10.50		2.3
Issued February 2020		1,015,001		1,025,001		6.30		3.6
		2,723,645		2,733,645	$	9.46
Equity Classified Warrants
Issued May 2016 - Bonwick		—		17,970	$	45.00		—
Issued July 2017 - Consulting ⁽³⁾		25,001		25,001		15.64		0.6
Issued April 2018 - Consulting		—		16,667		18.00		—
Issued August 2019 - Consulting		25,000		25,000		9.84		0.6
Issued April 2020 - Consulting		16,667		16,667		6.84		3.3
Issued December 2020 - Consulting		8,334		8,334		4.72		4.0
Issued April 2021 - Consulting		71,500		—		3.63		4.3
Issued August 2021 - Consulting		250,000		—		3.08		9.6
		396,502		109,639	$	4.59
Balance outstanding		3,120,147		2,843,284	$	8.51

⁽¹⁾ If the Company subdivides (by any stock split, stock dividend, recapitalization or otherwise) its outstanding shares of its common stock into a smaller number of shares, the warrant exercise price is proportionately reduced and the number of shares under outstanding warrants is proportionately increased. Additionally, if the Company combines (by combination, reverse stock split or otherwise) its outstanding shares of common stock into a smaller number of shares, the warrant exercise price is proportionately increased and the number of shares under outstanding warrants is proportionately decreased. Also, the Company may voluntarily reduce the warrant exercise price for its warrants issued in March 2019 and February 2017 and may voluntarily extend the contractual term of its warrants issued in February 2017.

⁽²⁾ Includes warrants to purchase 118,372 shares at an exercise price of $12.12, expiring December 22, 2023, and warrants to purchase 5,464 shares at an exercise price of $13.92, expiring June 21, 2023.

⁽³⁾ Includes warrants to purchase 16,667 shares at an exercise price of $14.46 and warrants to purchase 8,334 shares at an exercise price of $18.00.

Liability Classified Warrants

The Company uses the Black-Scholes option pricing model (BSM) to determine the fair value of its warrants at the date of issue and outstanding at each reporting date.

The risk-free interest rate assumption is based upon observed interest rates on zero coupon US Treasury bonds linearly interpolated to obtain a maturity period commensurate with the term of the warrants.

Estimated volatility is a measure of the amount by which the Company's stock price is expected to fluctuate each year during the expected life of the warrants. Beginning in 2020, only the volatility of the Company's own stock is used in the BSM as it now has sufficient historic data in its stock price.

The assumptions used in determining the fair value of the Company’s outstanding liability classified warrants are as follows:

	*Year Ended December 31,*
	*2021*		*2020*
Risk-free interest rate		0.1% to 1.1%		0.1% to 0.3%
Volatility		71.8% to 114.5%		113.7% to 127.4%
Expected life (years)		0.1 to 3.6		1.1 to 4.6
Dividend yield		—%		—%

A summary of the Company's liability classified warrant activity during the year ended December 31, 2021 and related information follows:

	*Number of Shares Under Warrant*			*Range of Warrant Exercise Price per Share*		*Weighted Average Exercise Price*		*Weighted Average Remaining Contractual Life (Years)*
Outstanding at December 31, 2020		2,733,645		6.60 to 16.80		$	9.45		3.6
Granted		—		6.30 to 6.30		$	—		—
Exercised		(10,000	)	6.60 to 6.60		$	6.60		—
Expired		—			—	$	—		—
Outstanding at December 31, 2021		2,723,645		6.30 to 16.80		$	9.46		2.6

Vested and Exercisable at December 31, 2021		2,723,645		6.30 to 16.80		$	9.46		2.6

In connection with the Company's stock offering that closed in February 2020, the Company issued warrants to purchase 937,501 shares of its common stock, that are exercisable six months from the date of issuance, at a price of $6.30 per share, subject to adjustment in certain circumstances, and expire five years from the date they are first exercisable, and issued Oppenheimer & Co. Inc. a warrant (Underwriter Warrant) to purchase up to 87,500 shares of its common stock with an exercise price of $6.30 per share, subject to adjustment in certain circumstances, which expires in February 2025.

For a summary of the changes in fair value associated with our warrant liability for the years ended December 31, 2021 and 2020, see Note 2. Basis of presentation, principles of consolidation and significant accounting policies – Fair Value of Financial Instruments.

Equity Classified Warrants

In April 2021, the Company granted equity-classified warrants to purchase 71,500 shares of common stock with a five-year term and an exercise price of $3.63 vesting quarterly over five years while services are being performed. In August 2021, the Company entered into a portfolio development advisory agreement with a related party entity, associated with Dr. Waldemar Priebe, and in connection with the agreement, the Company granted equity-classified warrants to purchase 250,000 shares of common stock with a ten-year term and an exercise price of $3.08. The August 2021 warrants vest (a) 50% upon execution of the agreement, provided the advisor does not terminate the agreement prior to the end of the one-year term; and (b) 50% 60 days after the end of the one-year term, subject to the Company's Board of Directors determining that the services provided have been adequately performed. Also, both the April 2021 and August 2021 warrants vest in full if there is a change of control event, as defined in the agreement.

In December 2020, equity warrants to purchase up to 8,334 shares of common stock were issued to a consultant, with vesting contingent on certain conditions focused on executing licensing arrangements. In April 2020, equity warrants to purchase up to 16,667 shares of common stock were issued to a consultant, with vesting contingent on certain conditions focused on generating up to $10.0 million of approved research and development expenditures on the Company's drug portfolio.

At December 31, 2021 the Company had 396,502 equity classified warrants outstanding and 186,560 warrants were exercisable. At December 31, 2020, the Company had 109,639 equity classified warrants outstanding and 85,472 were exercisable.

The Company recorded stock compensation expense for the non-employee consulting agreements of $516,000 and $5,000 for the years ended December 31, 2021 and 2020, respectively. At December 31, 2021, there was $548,000 of unrecognized stock compensation expense related to the Company's equity-classified warrants.